<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03159247</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00112614</org_study_id>
    <secondary_id>1K23EY025320-01A1</secondary_id>
    <nct_id>NCT03159247</nct_id>
  </id_info>
  <brief_title>The eyeGuide: Improving Glaucoma Self-management With a Personalized Behavior Change Program</brief_title>
  <acronym>eyeGuide</acronym>
  <official_title>The eyeGuide: Improving Glaucoma Self-management With a Personalized Behavior Change Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Research to Prevent Blindness</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to test the impact of two personalized technology based
      programs that may help improve adherence to glaucoma medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite evidence from randomized clinical trials that medication reduces vision loss from
      glaucoma, it remains the second leading cause of blindness in the United States. A critical
      barrier to preventing vision loss is that about one-half of glaucoma patients are essentially
      &quot;untreated&quot; because they do not adhere to their medications. Ineffective self-management
      behaviors and poor clinical outcomes disproportionately affect the most vulnerable members of
      US society. The increased burden of glaucoma due to an aging US population, together with a
      projected shortage of ophthalmologists, will make team-based care essential. There is a
      critical need to develop and test team-based, personalized behavior change interventions for
      glaucoma patients to improve medication adherence and the outcomes of care.

      Poor adherence to effective medications is a critical barrier to better outcomes in glaucoma
      patients. The World Health Organization stated that &quot;increasing the effectiveness of
      adherence interventions may have a far greater impact on the health of the population than
      any improvement in specific medical treatments.&quot; Once diagnosed with glaucoma, at least half
      of patients do not adhere to their glaucoma medication regimen, return for follow-up, or
      persist with their medications over the longer term. Patients who are not adherent have more
      severe visual field loss, which leads to steep declines in health-related quality of life and
      increased risk of falls and motor vehicle accidents.

      Adherence to glaucoma medications is rarely addressed during the clinical encounter because
      education and counseling programs are not part of standard glaucoma care. Focus groups have
      demonstrated that patients often have a poor understanding of glaucoma and its treatment. In
      addition to knowledge gaps, patients have numerous concrete and psychological barriers to
      managing their glaucoma. In addition, eye drop instillation is rarely taught, and many
      patients cannot properly instill their medications.

      Uniform, scripted approaches to improve adherence do not work. However, complex,
      individualized counseling interventions, especially those based in motivational interviewing
      (MI), have improved adherence and health outcomes in many chronic diseases. MI is a style of
      counseling that engages patients by discussing priorities and obstacles to facilitate
      intrinsic motivation to change health behavior. Few complex interventions based on these
      successful principles have been rigorously tested and none implemented into glaucoma care.
      The eyeGuide is a web-based personally tailored behavior change program based on MI
      principles, a systematic review of the glaucoma adherence literature, and data from focus
      groups, surveys and iterative beta-testing with glaucoma patients. It provides individually
      tailored disease information and support to facilitate MI-based conversations between
      patients and paraprofessional staff to improve medication adherence. Such technology-based
      electronic health (eHealth) innovations have great potential to extend the reach of
      physicians by enabling team-based care.

      In this pilot study, the study will test the impact of two personalized eHealth technologies
      on medication adherence among non-adherent glaucoma patients in a pre-post design: 1) real
      time automated adherence reminders; and 2) the eyeGuide counseling program. The study will
      explore the effects of these interventions on secondary outcomes including psychosocial
      mediators of adherence (e.g. motivation, self-efficacy, satisfaction), intraocular pressure
      (IOP), and IOP fluctuation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 12, 2017</start_date>
  <completion_date type="Anticipated">October 12, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 12, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a single group prospective behavioral intervention with a pre-post design. Adherence will be measured for three months at baseline, for an additional three months after an automated reminder system is initiated, for an additional six months during a personalized behavior change intervention and then for one year after the intervention.</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Electronically monitored glaucoma medication adherence</measure>
    <time_frame>24 months</time_frame>
    <description>electronic medication monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of days covered with medication</measure>
    <time_frame>24 months</time_frame>
    <description>monthly pharmacy refill data for glaucoma medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in self-reported medication adherence</measure>
    <time_frame>24 months</time_frame>
    <description>Two survey instruments will be used to determine the amount of change in overall adherence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in eye drop instillation technique</measure>
    <time_frame>4 months elapsed between 6 month and 10 month site visits</time_frame>
    <description>eye drop instillation technique will be video taped and analyzed on the 6 month and 10 month study visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Intra-ocular Pressure</measure>
    <time_frame>24 months</time_frame>
    <description>Intra-ocular pressure will be measured by Goldmann applanation tonometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Intra-ocular Pressure Fluctuation</measure>
    <time_frame>24 months</time_frame>
    <description>Intraocular pressure data will be analyzed to assess a change in pressure fluctuations</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Medication Adherence</condition>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>eyeGuide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two personalized eHealth interventions aimed to improve glaucoma medication adherence.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>eyeGuide</intervention_name>
    <description>The eyeGuide, a web-based tool to facilitate a personalized behavior change program for non-adherent glaucoma patients.</description>
    <arm_group_label>eyeGuide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of glaucoma, glaucoma suspect or ocular hypertension

          -  Taking ≥ 1 glaucoma medication

          -  Age ≥ 40 years

          -  Non-adherent to glaucoma medications by both self-report and three months of
             electronic medication monitoring (adherence &lt;80%)

        Exclusion Criteria:

          -  Cognitive impairment

          -  Severe mental illness

          -  Do not administer own glaucoma medications

          -  Do not speak English
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula A Newman-Casey, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurie A Taylor</last_name>
    <phone>(734) 232-8057</phone>
    <email>laurieat@med.umich.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Allen</last_name>
    <phone>(734) 763-6967</phone>
    <email>jjmn@med.umich.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula A Newman-Casey, MD, MS</last_name>
      <phone>734-763-6967</phone>
      <email>panewman@med.umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Laurie A Taylor</last_name>
      <phone>(734) 232-8057</phone>
      <email>laurieat@med.umich.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, Azuara-Blanco A, Bourne RR, Broadway DC, Cunliffe IA, Diamond JP, Fraser SG, Ho TA, Martin KR, McNaught AI, Negi A, Patel K, Russell RA, Shah A, Spry PG, Suzuki K, White ET, Wormald RP, Xing W, Zeyen TG. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015 Apr 4;385(9975):1295-304. doi: 10.1016/S0140-6736(14)62111-5. Epub 2014 Dec 19. Erratum in: Lancet. 2015 Jul 11;386(9989):136.</citation>
    <PMID>25533656</PMID>
  </reference>
  <reference>
    <citation>Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002 Oct;120(10):1268-79.</citation>
    <PMID>12365904</PMID>
  </reference>
  <reference>
    <citation>Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006 Mar;90(3):262-7.</citation>
    <PMID>16488940</PMID>
  </reference>
  <reference>
    <citation>Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005 Jun;112(6):953-61. Review.</citation>
    <PMID>15885795</PMID>
  </reference>
  <reference>
    <citation>Reardon G, Kotak S, Schwartz GF. Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Patient Prefer Adherence. 2011;5:441-63. doi: 10.2147/PPA.S23780. Epub 2011 Sep 23.</citation>
    <PMID>22003282</PMID>
  </reference>
  <reference>
    <citation>Murakami Y, Lee BW, Duncan M, Kao A, Huang JY, Singh K, Lin SC. Racial and ethnic disparities in adherence to glaucoma follow-up visits in a county hospital population. Arch Ophthalmol. 2011 Jul;129(7):872-8. doi: 10.1001/archophthalmol.2011.163.</citation>
    <PMID>21746977</PMID>
  </reference>
  <reference>
    <citation>Congdon N, O'Colmain B, Klaver CC, Klein R, Muñoz B, Friedman DS, Kempen J, Taylor HR, Mitchell P; Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004 Apr;122(4):477-85.</citation>
    <PMID>15078664</PMID>
  </reference>
  <reference>
    <citation>Lee PP, Hoskins HD Jr, Parke DW 3rd. Access to care: eye care provider workforce considerations in 2020. Arch Ophthalmol. 2007 Mar;125(3):406-10.</citation>
    <PMID>17353416</PMID>
  </reference>
  <reference>
    <citation>Sabate E. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization (WHO); 2003. Available at: http://www.who.int/chp/knowledge/publications/adherence_full_report.pdf. Accessed June 7, 2015.</citation>
  </reference>
  <reference>
    <citation>Kass MA, Gordon M, Morley RE Jr, Meltzer DW, Goldberg JJ. Compliance with topical timolol treatment. Am J Ophthalmol. 1987 Feb 15;103(2):188-93.</citation>
    <PMID>3812621</PMID>
  </reference>
  <reference>
    <citation>Newman-Casey PA, Blachley T, Lee PP, Heisler M, Farris KB, Stein JD. Patterns of Glaucoma Medication Adherence over Four Years of Follow-Up. Ophthalmology. 2015 Oct;122(10):2010-21. doi: 10.1016/j.ophtha.2015.06.039. Epub 2015 Aug 25.</citation>
    <PMID>26319441</PMID>
  </reference>
  <reference>
    <citation>Rossi GC, Pasinetti GM, Scudeller L, Radaelli R, Bianchi PE. Do adherence rates and glaucomatous visual field progression correlate? Eur J Ophthalmol. 2011 Jul-Aug;21(4):410-4. doi: 10.5301/EJO.2010.6112.</citation>
    <PMID>21140373</PMID>
  </reference>
  <reference>
    <citation>Sleath B, Blalock S, Covert D, Stone JL, Skinner AC, Muir K, Robin AL. The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity. Ophthalmology. 2011 Dec;118(12):2398-402. doi: 10.1016/j.ophtha.2011.05.013.</citation>
    <PMID>21856009</PMID>
  </reference>
  <reference>
    <citation>Stewart WC, Chorak RP, Hunt HH, Sethuraman G. Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. Am J Ophthalmol. 1993 Aug 15;116(2):176-81.</citation>
    <PMID>8352302</PMID>
  </reference>
  <reference>
    <citation>McKean-Cowdin R, Varma R, Wu J, Hays RD, Azen SP; Los Angeles Latino Eye Study Group. Severity of visual field loss and health-related quality of life. Am J Ophthalmol. 2007 Jun;143(6):1013-23. Epub 2007 Apr 2.</citation>
    <PMID>17399676</PMID>
  </reference>
  <reference>
    <citation>McKean-Cowdin R, Wang Y, Wu J, Azen SP, Varma R; Los Angeles Latino Eye Study Group. Impact of visual field loss on health-related quality of life in glaucoma: the Los Angeles Latino Eye Study. Ophthalmology. 2008 Jun;115(6):941-948.e1. Epub 2007 Nov 12.</citation>
    <PMID>17997485</PMID>
  </reference>
  <reference>
    <citation>Freeman EE, Muñoz B, West SK, Jampel HD, Friedman DS. Glaucoma and quality of life: the Salisbury Eye Evaluation. Ophthalmology. 2008 Feb;115(2):233-8. Epub 2007 Jul 26.</citation>
    <PMID>17655930</PMID>
  </reference>
  <reference>
    <citation>Varma R, Wu J, Chong K, Azen SP, Hays RD; Los Angeles Latino Eye Study Group. Impact of severity and bilaterality of visual impairment on health-related quality of life. Ophthalmology. 2006 Oct;113(10):1846-53. Epub 2006 Aug 4.</citation>
    <PMID>16889831</PMID>
  </reference>
  <reference>
    <citation>Haymes SA, Leblanc RP, Nicolela MT, Chiasson LA, Chauhan BC. Risk of falls and motor vehicle collisions in glaucoma. Invest Ophthalmol Vis Sci. 2007 Mar;48(3):1149-55.</citation>
    <PMID>17325158</PMID>
  </reference>
  <reference>
    <citation>Sleath B, Blalock SJ, Carpenter DM, Sayner R, Muir KW, Slota C, Lawrence SD, Giangiacomo AL, Hartnett ME, Tudor G, Goldsmith JA, Robin AL. Ophthalmologist-patient communication, self-efficacy, and glaucoma medication adherence. Ophthalmology. 2015 Apr;122(4):748-54. doi: 10.1016/j.ophtha.2014.11.001. Epub 2014 Dec 24.</citation>
    <PMID>25542521</PMID>
  </reference>
  <reference>
    <citation>Sleath BL, Blalock SJ, Muir KW, Carpenter DM, Lawrence SD, Giangiacomo AL, Goldsmith JA, Hartnett ME, Slota C, Robin AL. Determinants of Self-Reported Barriers to Glaucoma Medicine Administration and Adherence: A Multisite Study. Ann Pharmacother. 2014 Jul;48(7):856-862. Epub 2014 Apr 1.</citation>
    <PMID>24692604</PMID>
  </reference>
  <reference>
    <citation>Lacey J, Cate H, Broadway DC. Barriers to adherence with glaucoma medications: a qualitative research study. Eye (Lond). 2009 Apr;23(4):924-32. doi: 10.1038/eye.2008.103. Epub 2008 Apr 25.</citation>
    <PMID>18437182</PMID>
  </reference>
  <reference>
    <citation>Stryker JE, Beck AD, Primo SA, Echt KV, Bundy L, Pretorius GC, Glanz K. An exploratory study of factors influencing glaucoma treatment adherence. J Glaucoma. 2010 Jan;19(1):66-72. doi: 10.1097/IJG.0b013e31819c4679.</citation>
    <PMID>20075676</PMID>
  </reference>
  <reference>
    <citation>Taylor SA, Galbraith SM, Mills RP. Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study. J Ocul Pharmacol Ther. 2002 Oct;18(5):401-9.</citation>
    <PMID>12419091</PMID>
  </reference>
  <reference>
    <citation>Lunnela J, Kääriäinen M, Kyngäs H. The views of compliant glaucoma patients on counselling and social support. Scand J Caring Sci. 2010 Sep;24(3):490-8. doi: 10.1111/j.1471-6712.2009.00739.x.</citation>
    <PMID>20210901</PMID>
  </reference>
  <reference>
    <citation>Newman-Casey PA, Robin AL, Blachley T, Farris K, Heisler M, Resnicow K, Lee PP. The Most Common Barriers to Glaucoma Medication Adherence: A Cross-Sectional Survey. Ophthalmology. 2015 Jul;122(7):1308-16. doi: 10.1016/j.ophtha.2015.03.026. Epub 2015 Apr 24.</citation>
    <PMID>25912144</PMID>
  </reference>
  <reference>
    <citation>Friedman DS, Hahn SR, Gelb L, Tan J, Shah SN, Kim EE, Zimmerman TJ, Quigley HA. Doctor-patient communication, health-related beliefs, and adherence in glaucoma results from the Glaucoma Adherence and Persistency Study. Ophthalmology. 2008 Aug;115(8):1320-7, 1327.e1-3. doi: 10.1016/j.ophtha.2007.11.023. Epub 2008 Mar 5.</citation>
    <PMID>18321582</PMID>
  </reference>
  <reference>
    <citation>Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003 Oct;12(5):393-8.</citation>
    <PMID>14520147</PMID>
  </reference>
  <reference>
    <citation>Hennessy AL, Katz J, Covert D, Kelly CA, Suan EP, Speicher MA, Sund NJ, Robin AL. A video study of drop instillation in both glaucoma and retina patients with visual impairment. Am J Ophthalmol. 2011 Dec;152(6):982-8. doi: 10.1016/j.ajo.2011.05.015. Epub 2011 Aug 6.</citation>
    <PMID>21821228</PMID>
  </reference>
  <reference>
    <citation>Sleath B, Blalock SJ, Stone JL, Skinner AC, Covert D, Muir K, Robin AL. Validation of a short version of the glaucoma medication self-efficacy questionnaire. Br J Ophthalmol. 2012 Feb;96(2):258-62. doi: 10.1136/bjo.2010.199851. Epub 2011 May 24.</citation>
    <PMID>21610264</PMID>
  </reference>
  <reference>
    <citation>Waterman H, Evans JR, Gray TA, Henson D, Harper R. Interventions for improving adherence to ocular hypotensive therapy. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD006132. doi: 10.1002/14651858.CD006132.pub3. Review.</citation>
    <PMID>23633333</PMID>
  </reference>
  <reference>
    <citation>Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, Agoritsas T, Mistry N, Iorio A, Jack S, Sivaramalingam B, Iserman E, Mustafa RA, Jedraszewski D, Cotoi C, Haynes RB. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014 Nov 20;(11):CD000011. doi: 10.1002/14651858.CD000011.pub4. Review.</citation>
    <PMID>25412402</PMID>
  </reference>
  <reference>
    <citation>Newman-Casey PA, Weizer JS, Heisler M, Lee PP, Stein JD. Systematic review of educational interventions to improve glaucoma medication adherence. Semin Ophthalmol. 2013 May;28(3):191-201. doi: 10.3109/08820538.2013.771198. Review.</citation>
    <PMID>23697623</PMID>
  </reference>
  <reference>
    <citation>Newman-Casey PA, Shtein RM, Coleman AL, Herndon L, Lee PP. Why Patients With Glaucoma Lose Vision: The Patient Perspective. J Glaucoma. 2016 Jul;25(7):e668-75. doi: 10.1097/IJG.0000000000000320.</citation>
    <PMID>26317482</PMID>
  </reference>
  <reference>
    <citation>Miller WR and Rollnick S. Motivational Interviewing: Helping people change, 3rd edition. 2013; Guilford Press, New York, NY.</citation>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2017</study_first_submitted>
  <study_first_submitted_qc>May 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2017</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Paula Anne Newman-Casey</investigator_full_name>
    <investigator_title>Assistant Professor of Ophthalmology and Visual Sciences</investigator_title>
  </responsible_party>
  <keyword>education</keyword>
  <keyword>counseling</keyword>
  <keyword>motivational interviewing</keyword>
  <keyword>tailoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

